Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07243405

Neurostimulation for Sleep Disordered Breathing (SDB)

This is a study to determine if the Lunair Alpha System is safe and effective for treating moderate to severe sleep disordered breathing.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Paitilla

Panama City, Provincia de Panamá, Panama

Location status: Recruiting

Location contact

Kris VP, Clinical Operations

CONTACT

[email protected]

1-866-675-4430

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject does not tolerate, not compliant to, or have access to alternative Sleep Disordered Breathing treatments
  • Subject has moderate to severe sleep disordered breathing as diagnosed by PSG

Exclusion criteria

  • Subject is taking opioids, narcotics, sleep or psychotic medications or supplements that may alter consciousness, the pattern of respiration, sleep architecture, or with known effect on sleep-wake function or alertness.
  • Any reason for which, in the judgement of the investigator, the subject is considered to be a poor study candidate
  • Subject has previous upper respiratory tract (URT) surgery or procedure (e.g., uvula, soft palate or tonsils) within 60 days prior to Screening PSG.
  • Subject has a need for chronic supplemental oxygen therapy for any reason
  • Subject has other sleep disorders or sleep hygiene behaviors that confound functional assessments of sleepiness
  • Subject has severe chronic kidney disease
  • Subject exhibits ongoing misuse of alcohol, tobacco, caffeine, or recreational drugs that would impact either the results of or the participation in a sleep study
  • Subject conducts work or regular activities requiring vigilance
  • Subject is unwilling or unable to refrain from consumption of alcoholic beverages for 24 hours prior to the start of each PSG study
  • Subject is unwilling or unable to refrain from sleep disordered breathing treatments or devices
  • Subject has an active systemic infection at the time of implant
  • Subject has clinical evidence of immunodeficiency
  • Any condition likely to require future MRI or diathermy
  • Subject is pregnant
  • Subject has severe nasal obstruction that could restrict airflow
  • Subject has any trauma to the upper airway
  • Subject has previous surgical resection, prior or current radiation therapy for cancer or congenital malformations in the larynx, tongue, or throat

Treatment and study plan

Neuro stimulator implant

Device

Neuro stimulator for treating sleep disordered breathing

Primary outcomes

  1. Safety Endpoint - assessment of procedure or device related adverse events

    Time frame: enrollment to 12 months post-implant

    Incidence of adverse events (AEs) related to the Lunair system or procedure

Secondary outcomes

  1. Improvement in sleep disordered breathing per sleep study

    Time frame: six month, 12 month and 24 month post implant

    Improvement in sleep disordered breathing at 6,12 and 24 months post implant during an attended sleep study

Study contacts

Contact information is provided by the study sponsor or research team.

Kris VP, Clinical Operations

CONTACT

[email protected]

1-866-675-4430

Sponsors and collaborators

Lead sponsor

Lunair Medical

Industry

Registry information

Official study title

The Evaluation of Neuro Stimulation for Treatment of Sleep Disordered Breathing

Acronym: ECLIPSE 2

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Nov 21, 2025
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.